Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients
Abstract
BACKGROUND AND AIMS
To investigate the impact of incident urinary tract infection (UTI) and subsequent sodium-glucose cotransporter-2 (SGLT2) inhibitors discontinuation on clinical outcomes among patients with type 2 diabetes mellitus (T2DM) prescribed SGLT2 inhibitors.
METHODS
This territory-wide cohort study analysed patients with T2DM prescribed SGLT2 inhibitors from January 2015 to June 2022. Primary outcomes included primary cardiovascular composite outcomes (heart failure hospitalization, stroke, myocardial infarction, or all-cause mortality) and primary renal composite outcomes (50% decline in estimated glomerular filtration rate [eGFR], end-stage renal failure, or all-cause mortality). The secondary outcome was recurrent UTI. A target trial emulation was applied to estimate the impact of discontinuing SGLT2 inhibitors.
RESULTS
Among 61 606 eligible patients, 3921 (6.36%) had at least one UTI incidence during follow-up. Patients with incident UTI exhibited a higher risk of primary cardiovascular composite outcomes [hazards ratio (HR): 3.18, 95% confidence interval (CI): 2.88-3.51] and primary renal composite outcomes (HR: 2.51, 95% CI: 2.32-2.72) compared to those without UTI. Following a UTI, 32.31% of patients discontinued SGLT2 inhibitors. Discontinuation was associated with a higher cardiovascular (HR: 1.35, 95% CI: 1.20-1.53) and renal (HR: 1.35, 95% CI: 1.21-1.51) risks compared to continued use, while the risk of recurrent UTI was similar (HR: 0.96, 95% CI:…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 61 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.